Friends of NPACE Podcast | Season 2 Episode 16: Type 2 Diabetes Medications: The intersection of new science and guidelines
-
Register
- User - Free!
In this episode of the Friends of NPACE Podcast join endocrinology specialist and Family Nurse Practitioner Gary Graf and NPACE Executive Director and nurse practitioner for an in depth discussion of managing diabetic medications in light of the new 2025 ADA Standards of Diabetes Care. This episode is worth 0.5 hours of continuing education credit, with 0.5 hours of pharmacology credit.
This podcast and the continuing education credit is due in thanks to a generous educational grant by Novo.
*Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.
This session is supported by an educational grant from Novo Nordisk.
Credits: 0.50 Contact Hours; 0.50 are Pharmacology
Expiration Date: May 14th, 2026
FREE
Gary Graf, MSN, ARNP-C
Family Nurse Practitioner (BC)
Cotton-O'Neil Diabetes and Endocrinology Center
Gary Graf is a Nurse Practitioner from Topeka, Kansas. He started practicing Family Medicine for 3 years but has done Diabetes and Endocrinology for the past 20 years. For 21 years he simultaneously did Urgent Care on weekends. He has been the Sub-Investigator in over 350 clinical trials in the field of Diabetes, Hypertension, Diabetic Kidney Disease as well as many Cardio-Vascular Outcome Trials. He has inserted over 350 implantable continuing glucose monitors. He and his wife have ten children and eight grandchildren. His hobbies include camping and fishing. He has climbed 50 of the 58 Colorado 14ers.
After listening to this podcast learners will:
(1) To increase APP/PCP understanding of current issues related to type 2 diabetes and treatment.
(2) To advance knowledge among PCPs about the differentiation of current and emerging treatments for T2DM.
(3) To help clinicians make decisions on treatment based on the intersection of unique patient needs, comorbidities, and these newer drug classes (GLP-1 RA, GIP, and SGLT2)
(4) Identify key cautions or prescribing pearls with newer drug classes.
Obtain Your Credits
To earn credits for this activity, you must complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile dashboard transcript for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 0.50 contact hours, of which 0.50 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720.
Faculty
Contributing faculty, Gary Graf, MSN, ARNP-C has disclosed no relevant financial relationships.
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
This session is supported by an educational grant from Novo Nordisk.
